Metformin/nateglinide

Drug Profile

Metformin/nateglinide

Alternative Names: Nateglinide/metformin

Latest Information Update: 28 Apr 2016

Price : $50

At a glance

  • Originator Ildong Pharmaceutical
  • Class Antihyperglycaemics; Aromatic amino acids; Biguanides; Cyclohexanes; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Insulinotropin agonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 01 Dec 2012 Ildong Pharmaceutical completes a phase I trial in Healthy volunteers in South Korea (NCT02088918)
  • 01 Oct 2012 Phase-I clinical trials in Type-2 diabetes mellitus (in volunteers) in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top